Earnings summaries and quarterly performance for Verastem.
Executive leadership at Verastem.
Board of directors at Verastem.
Research analysts who have asked questions during Verastem earnings calls.
AN
Anish Nikhanj
RBC Capital Markets
1 question for VSTM
Also covers: APTO, CRMD, EXEL +6 more
A
Anshi
Jefferies
1 question for VSTM
Graig Suvannavejh
Mizuho Securities
1 question for VSTM
Also covers: ADAP, ADVM, ALEC +12 more
James Molloy
Alliance Global Partners
1 question for VSTM
Also covers: ABEO, ACXP, AIM +11 more
Justin Zelin
BTIG, LLC
1 question for VSTM
Also covers: BCAB, CASI, GLMD +9 more
KH
Kelly Hsu
Jefferies
1 question for VSTM
Leonid Timashev
RBC Capital Markets
1 question for VSTM
Also covers: ADCT, ALKS, AXSM +10 more
Michael Schmidt
Guggenheim Securities
1 question for VSTM
Also covers: ADAP, ADCT, ARVN +20 more
Paul Jeng
Guggenheim Partners
1 question for VSTM
Also covers: ADAP, BPMC, IMCR +2 more
PS
Pete Stavropoulos
Cantor Fitzgerald
1 question for VSTM
Also covers: ABOS, ALEC, ARCT +9 more
Sean Lee
H.C. Wainwright & Co.
1 question for VSTM
Also covers: ATEC, CASI, CTSO +3 more
YZ
Yuan Zhi
B. Riley Financial, Inc.
1 question for VSTM
Also covers: HYPR, LNTH, MIR +4 more
Recent press releases and 8-K filings for VSTM.
Verastem Provides Updates on Commercial Product Performance and Clinical Pipeline Progress
VSTM
Product Launch
New Projects/Investments
Revenue Acceleration/Inflection
- Verastem's commercial product, AVMAPKI FAKZYNJA for LGSOC, has shown a successful launch with sales increasing over 50% from Q2 to Q3 to Q4 and patients staying on therapy for an average of 18 months.
- The confirmatory RAMP 301 trial for LGSOC has completed accrual with 300 patients and is expected to have a readout around mid-2027 or earlier, potentially expanding the indication to include KRAS wild type patients, addressing 6,000 to 10,000 patients in the U.S..
- The RAMP 205 study for pancreatic cancer reported an 83% confirmed response rate in 12 patients and will provide durability data for 29 patients by mid-2026.
- The KRAS G12D inhibitor, VS-7375, has shown strong efficacy in Chinese trials with 58% response rate in second-line pancreatic and 69% in advanced metastatic lung cancer, and the U.S. Phase I trial is showing improved tolerability, potentially allowing higher doses up to 900 mg QD.
- Verastem is pursuing broad opportunities for VS-7375, including single-agent and combination therapies in lung, pancreatic, and colorectal cancers, with potential for accelerated approval.
Feb 11, 2026, 7:00 PM
Verastem Provides Updates on Commercial Product and Clinical Pipeline
VSTM
Product Launch
New Projects/Investments
Revenue Acceleration/Inflection
- Verastem's commercial product, AVMAPKI FAKZYNJA, for LGSOC has achieved a successful launch, surpassing analyst consensus for three consecutive quarters and demonstrating over a 50% increase in sales from Q2 to Q3 to Q4.
- The confirmatory RAMP 301 trial for LGSOC has completed accrual with a readout anticipated around mid-next year, and the Data Monitoring Board recommended a planned increase of 30 patients to both wild type and mutant cohorts.
- Initial results from the RAMP 205 study in pancreatic cancer showed an 83% confirmed response rate in 12 patients, with further data for 29 patients, including durability insights, expected to be reported mid-this year.
- The KRAS G12D inhibitor, VS-7375, has shown high response rates (58% in second-line pancreatic, 69% in advanced metastatic lung cancer) in partner studies, and the US Phase I trial is demonstrating improved tolerability with potential for accelerated approval and broad development.
Feb 11, 2026, 7:00 PM
Verastem Provides Updates on Commercial Performance, Clinical Trials, and Pipeline Development
VSTM
Product Launch
New Projects/Investments
Revenue Acceleration/Inflection
- Verastem's commercial product, avutometinib and defactinib, for low-grade serous ovarian cancer (LGSOC) has achieved a successful launch, with sales increasing over 50% from Q2 to Q3 to Q4. The confirmatory RAMP 301 trial has completed accrual, with results expected around mid-2027 or earlier, potentially expanding the U.S. market to 6,000 to 10,000 patients.
- The RAMP 205 study for pancreatic cancer demonstrated an 83% confirmed response rate in 12 patients using a triplet combination, and data on 29 patients with durability will be reported mid-2026.
- The KRAS G12D inhibitor, VS-7375, has shown high response rates of 58% in second-line pancreatic cancer and 69% in advanced metastatic lung cancer in Chinese trials. U.S. trials are exhibiting improved tolerability, with potential for accelerated approval as a single agent and broad development across multiple cancer types.
Feb 11, 2026, 7:00 PM
Verastem Oncology Provides Preliminary Q4 and Full Year 2025 Revenue and Business Updates
VSTM
Earnings
Product Launch
Guidance Update
- Verastem Oncology reported preliminary, unaudited net product revenues for AVMAPKI FAKZYNJA CO-PACK of approximately $17.5 million for the fourth quarter of 2025 and approximately $30.9 million for the full year 2025, following its U.S. FDA approval in May 2025.
- As of December 31, 2025, the company had preliminary unaudited cash, cash equivalents, and investments of $205 million, with a pro-forma total of $234 million including proceeds from warrant exercises, projecting a cash runway into the first half of 2027.
- For 2026, Verastem plans to maximize adoption of AVMAPKI FAKZYNJA CO-PACK in the U.S. and accelerate the clinical path for VS-7375, its oral KRAS G12D inhibitor, with potential registration-directed clinical trials.
- The company anticipates the LGSOC commercial launch and development program for AVMAPKI FAKZYNJA CO-PACK to be self-sustaining by the second half of 2026.
Feb 4, 2026, 12:30 PM
Verastem Oncology Reports Preliminary 2025 Financials and Outlines 2026 Strategic Priorities
VSTM
Earnings
Guidance Update
Product Launch
- Verastem Oncology reported preliminary, unaudited net product revenues for AVMAPKI FAKZYNJA CO-PACK of approximately $17.5 million for the fourth quarter of 2025 and $30.9 million for the full year 2025.
- As of December 31, 2025, the company had $205 million in cash, cash equivalents, and investments, with a pro-forma $234 million including net proceeds from exercised cash warrants, providing a cash runway into the first half of 2027.
- The company's 2026 priorities include maximizing the commercial launch of AVMAPKI FAKZYNJA CO-PACK, which received U.S. FDA approval in May 2025 for KRAS-mutated recurrent LGSOC, and advancing its clinical development program for VS-7375, a KRAS G12D inhibitor.
- An interim update on the Phase 1/2 trial of VS-7375 is expected in 1H 2026, and a topline readout of the primary endpoint in the RAMP 301 trial is anticipated in mid-2027.
Feb 4, 2026, 12:30 PM
Verastem, Inc. Updates Corporate Presentation with Q3 2025 Financials and 2026 Priorities
VSTM
Product Launch
Guidance Update
New Projects/Investments
- Verastem, Inc. reported net product revenue of $11.2 million for Q3 2025, following the May 8, 2025, FDA approval and commercial launch of AVMAPKIFAKZYNJACO-PACK for KRAS mutant-type recurrent Low-Grade Serous Ovarian Cancer.
- The company ended Q3 2025 with $137.7 million in cash, cash equivalents, and short-term investments, with a pro-forma amount of $235.0 million, extending its cash runway into 1H 2027.
- Key priorities for 2026 include maximizing the commercial launch of AVMAPKIFAKZYNJACO-PACK, continuing the RAMP 301 confirmatory Phase 3 trial, and generating monotherapy and combination data with VS-7375 to inform its registration path.
- Upcoming milestones include an update on the RAMP 205 expansion cohort and an interim update for VS-7375 monotherapy in 1H 2026, with RAMP 301 topline data expected by mid-2027.
Jan 8, 2026, 9:16 PM
Verastem Discontinues RAMP-203 Trial, Pivots to VS-7375
VSTM
New Projects/Investments
Insider Selling
Demand Weakening
- Verastem Oncology is discontinuing the RAMP-203 trial for advanced KRAS G12C-mutant non-small cell lung cancer, citing the emergence of next-generation G12C inhibitors with higher response rates.
- The company plans to reallocate resources to VS-7375, an oral KRAS G12D inhibitor, which has shown approximately a 69% response rate in advanced NSCLC.
- This announcement led to a 2% after-hours stock decline and comes amid clear financial strain, including large negative margins, an Altman Z-Score in the distress zone, and 12 insider selling transactions in the prior three months.
- Verastem's trailing-12-month revenue was about $13.38 million, with a market capitalization of roughly $584.5 million and a three-year revenue growth rate of about 25.7%.
Dec 29, 2025, 9:10 PM
Verastem Oncology Discontinues RAMP 203 Trial, Prioritizes Other Programs
VSTM
New Projects/Investments
Product Launch
- Verastem Oncology will discontinue the RAMP 203 Phase 1/2 clinical trial for advanced KRAS G12C-mutated non-small cell lung cancer (NSCLC) to strategically prioritize resources on the clinical development of VS-7375 and the RAMP 205 trial.
- The decision to discontinue RAMP 203 was made following an evaluation of interim data as of November 26, 2025, and reflects the evolving treatment landscape for KRAS G12C inhibitors.
- The company is prioritizing VS-7375, an oral KRAS G12D (ON/OFF) inhibitor, which demonstrated a 69% response rate (11 of 16) in advanced KRAS G12D NSCLC.
- Interim data from RAMP 203 showed that for G12C-inhibitor treatment-naïve patients in the doublet combination, the overall response rate was 40% (12/30) and the median progression-free survival was 11.1 months.
- Separately, the FDA approved AVMAPKI FAKZYNJA CO-PACK on May 8, 2025, for the treatment of adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer.
Dec 29, 2025, 9:01 PM
Verastem Announces Strategic Leadership Changes and COO Departure
VSTM
Board Change
Management Change
Executive Compensation
- Verastem Oncology announced strategic leadership changes, appointing John Johnson as Chairman of the Board and Michael Kauffman, M.D., Ph.D., as President of Development.
- Matthew Ros, Chief Operating Officer, departed the company effective December 19, 2025, as part of an operational streamlining.
- In connection with his separation, Mr. Ros will receive nine months of base salary continuation totaling $363,750.00, COBRA premium payments for nine months, and a pro-rated bonus of $196,425.00 for 2025.
- The company completed additional patient enrollment for its RAMP 301 Phase 3 confirmatory trial in recurrent LGSOC, with topline data anticipated in mid-2027.
Dec 19, 2025, 10:21 PM
Verastem Oncology Announces Leadership Changes and Clinical Trial Progress
VSTM
Board Change
Management Change
Product Launch
- John Johnson has been appointed Chairman of the Board, succeeding Michael Kauffman, M.D., Ph.D., who will now serve as President of Development and join the executive leadership team.
- Matthew Ros, Chief Operating Officer, is departing the organization as part of an operational streamlining.
- The commercial launch of AVMAPKI FAKZYNJA CO-PACK is progressing, following its FDA approval on May 8, 2025, for KRAS-mutated recurrent LGSOC.
- The RAMP 301 Phase 3 confirmatory trial for recurrent LGSOC has completed additional patient enrollment, with topline data anticipated in mid-2027.
Dec 15, 2025, 9:01 PM
Quarterly earnings call transcripts for Verastem.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more